A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

NCT04452214 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Urothelial Carcinoma
Malignant Melanoma
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: CAN04
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Cantargia AB